$127.00
7.716.46%
At close: -
$117.30
-9.70-7.64%
After Hours: Nov 6, 7:31 PM EDT
Comments
Loading...
Spruce Biosciences Analyst Ratings and Price Targets | NASDAQ:SPRB | Benzinga
Spruce Biosciences Inc has a consensus price target of $85.5 based on the ratings of 9 analysts. The high is $254 issued by JMP Securities on October 28, 2025. The low is $0.5 issued by RBC Capital on April 16, 2025. The 3 most-recent analyst ratings were released by JMP Securities, Leerink Partners, and RBC Capital on October 28, 2025, October 21, 2025, and April 16, 2025, respectively. With an average price target of $138.17 between JMP Securities, Leerink Partners, and RBC Capital, there's an implied 17.79% upside for Spruce Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Leerink Partners
RBC Capital
SVB Leerink
Credit Suisse
1calculated from analyst ratings
Analyst Ratings for Spruce Biosciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/28/2025 | 116.54% | JMP Securities | → $254 | Upgrade | Market Perform → Market Outperform | |||
10/21/2025 | 36.4% | Leerink Partners | $10 → $160 | Maintains | Market Perform | |||
04/16/2025 | -99.57% | RBC Capital | $1.5 → $0.5 | Maintains | Sector Perform | |||
12/16/2024 | — | HC Wainwright & Co. | — | Reiterates | Neutral → Neutral | |||
12/12/2024 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
12/11/2024 | -97.44% | JMP Securities | $3 → $3 | Downgrade | Market Outperform → Market Perform | |||
12/11/2024 | -98.72% | RBC Capital | $2 → $1.5 | Reiterates | Sector Perform → Sector Perform | |||
12/11/2024 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
11/12/2024 | -98.29% | RBC Capital | $2 → $2 | Reiterates | Sector Perform → Sector Perform | |||
08/19/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
08/13/2024 | -98.29% | RBC Capital | $2 → $2 | Reiterates | Sector Perform → Sector Perform | |||
06/13/2024 | -97.44% | Oppenheimer | $4 → $3 | Maintains | Outperform | |||
06/05/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
05/14/2024 | — | HC Wainwright & Co. | — | Reiterates | → Neutral | |||
03/14/2024 | -98.29% | RBC Capital | $9 → $2 | Downgrade | Outperform → Sector Perform | |||
03/14/2024 | -97.44% | JMP Securities | $8 → $3 | Maintains | Market Outperform | |||
03/14/2024 | — | HC Wainwright & Co. | — | Downgrade | Buy → Neutral | |||
03/14/2024 | -98.29% | Leerink Partners | $9 → $2 | Downgrade | Outperform → Market Perform | |||
03/14/2024 | — | Ladenburg Thalmann | — | Downgrade | Buy → Neutral | |||
03/14/2024 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
03/05/2024 | -92.33% | RBC Capital | $9 → $9 | Reiterates | Outperform → Outperform | |||
02/26/2024 | -92.33% | RBC Capital | $8 → $9 | Maintains | Outperform | |||
02/21/2024 | -91.47% | Guggenheim | → $10 | Initiates | → Buy | |||
11/20/2023 | -91.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
09/13/2023 | -93.18% | RBC Capital | → $8 | Reiterates | Outperform → Outperform | |||
09/13/2023 | -91.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
09/08/2023 | -92.33% | SVB Leerink | $3 → $9 | Upgrade | Market Perform → Outperform | |||
08/18/2023 | -94.03% | Oppenheimer | $8 → $7 | Maintains | Outperform | |||
08/18/2023 | -91.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
08/16/2023 | -93.18% | JMP Securities | $7 → $8 | Maintains | Outperform | |||
08/15/2023 | -93.18% | RBC Capital | → $8 | Reiterates | Outperform → Outperform | |||
06/13/2023 | -91.47% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy | |||
05/23/2023 | -93.18% | Oppenheimer | → $8 | Reiterates | Outperform → Outperform | |||
05/16/2023 | -94.03% | JMP Securities | $7 → $7 | Reiterates | Market Outperform → Market Outperform | |||
05/16/2023 | -93.18% | RBC Capital | → $8 | Reiterates | Outperform → Outperform | |||
05/16/2023 | -96.59% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform | |||
03/23/2023 | -91.47% | HC Wainwright & Co. | $20 → $10 | Maintains | Buy | |||
03/20/2023 | -93.18% | RBC Capital | → $8 | Reiterates | → Outperform | |||
03/17/2023 | -94.03% | JMP Securities | $7 → $7 | Maintains | Market Outperform | |||
03/17/2023 | -96.59% | Credit Suisse | → $4 | Reiterates | → Outperform | |||
02/13/2023 | -93.18% | RBC Capital | $9 → $8 | Maintains | Outperform | |||
01/08/2023 | -93.18% | JMP Securities | $8 → $8 | Maintains | Outperform | |||
11/17/2022 | -93.18% | Oppenheimer | $13 → $8 | Maintains | Outperform | |||
11/16/2022 | -93.18% | JMP Securities | → $8 | Initiates | → Market Outperform |
FAQ
What is the target price for Spruce Biosciences (SPRB) stock?
The latest price target for Spruce Biosciences (NASDAQ:SPRB) was reported by JMP Securities on October 28, 2025. The analyst firm set a price target for $254.00 expecting SPRB to rise to within 12 months (a possible 116.54% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spruce Biosciences (SPRB)?
The latest analyst rating for Spruce Biosciences (NASDAQ:SPRB) was provided by JMP Securities, and Spruce Biosciences upgraded their market outperform rating.
When was the last upgrade for Spruce Biosciences (SPRB)?
The last upgrade for Spruce Biosciences Inc happened on October 28, 2025 when JMP Securities raised their price target to $254. JMP Securities previously had a market perform for Spruce Biosciences Inc.
When was the last downgrade for Spruce Biosciences (SPRB)?
The last downgrade for Spruce Biosciences Inc happened on December 11, 2024 when JMP Securities changed their price target from $3 to $3 for Spruce Biosciences Inc.
When is the next analyst rating going to be posted or updated for Spruce Biosciences (SPRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spruce Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spruce Biosciences was filed on October 28, 2025 so you should expect the next rating to be made available sometime around October 28, 2026.
Is the Analyst Rating Spruce Biosciences (SPRB) correct?
While ratings are subjective and will change, the latest Spruce Biosciences (SPRB) rating was a upgraded with a price target of $0.00 to $254.00. The current price Spruce Biosciences (SPRB) is trading at is $117.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
